Skip to main
LFMD

LifeMD (LFMD) Stock Forecast & Price Target

LifeMD (LFMD) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

LifeMD Inc demonstrated a significant growth trajectory in its Telehealth segment, with a 14% year-over-year increase in its active subscriber base, reaching 310,818 by the end of the third quarter of 2025. The company's total revenue rose to $60.2 million, reflecting a 12.7% increase year-over-year, largely driven by a 17.4% growth in Telehealth revenue, which reached $47.3 million. The firm has also re-established its growth momentum through strategic product offerings, such as the introduction of GLP-1 medications at competitive pricing, indicating an overall improvement in market conditions and robust demand for its telehealth services.

Bears say

LifeMD Inc. reported revenue of $60.2 million for the latest quarter, reflecting a 13% year-over-year increase, but this figure fell short of consensus expectations, indicating a slowdown in top-line growth due to reduced marketing of compounded products. The company also missed adjusted EBITDA projections, reporting $5.1 million—20% higher than the previous year—but below guidance, highlighting ongoing profitability challenges amidst competitive pressures in the telehealth sector. Additionally, LifeMD has lowered its full-year 2025 revenue guidance for the telehealth segment to between $192 million and $193 million, following increased competition from lower-cost alternatives and signaling potential operational hurdles that may adversely affect future growth and investor confidence.

LifeMD (LFMD) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LifeMD (LFMD) Forecast

Analysts have given LifeMD (LFMD) a Buy based on their latest research and market trends.

According to 7 analysts, LifeMD (LFMD) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LifeMD (LFMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.